Boston Family Office LLC Has $22.85 Million Holdings in Stryker Co. (NYSE:SYK)

Boston Family Office LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 0.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,259 shares of the medical technology company’s stock after purchasing an additional 157 shares during the period. Stryker comprises 1.5% of Boston Family Office LLC’s holdings, making the stock its 20th largest holding. Boston Family Office LLC’s holdings in Stryker were worth $22,853,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in SYK. Centennial Bank AR grew its position in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $36,000. HBW Advisory Services LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. Hara Capital LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. Finally, Grove Bank & Trust boosted its position in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after acquiring an additional 56 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $384.85 on Monday. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20. The company has a fifty day moving average price of $366.20 and a 200-day moving average price of $349.63. The company has a market capitalization of $146.71 billion, a P/E ratio of 41.25, a PEG ratio of 2.90 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter last year, the firm earned $2.46 earnings per share. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. increased their price target on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Wolfe Research started coverage on shares of Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective for the company. Evercore ISI increased their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, BTIG Research increased their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock valued at $24,825,275 over the last quarter. Insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.